Duchenne, Solid Biosciences and gene therapy

Solid Biosciences (NASDAQ:SLDB – Free Report) had its price objective boosted by Chardan Capital from $15.00 to $16.00 in a report published on Wednesday morning,Benzinga reports. The brokerage ...
Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic ...
The deal priced at last closing price of $4.03. Jefferies, Leerink and William Blair are acting as joint book running managers for the ...